{"id":294,"date":"2021-01-11T01:00:00","date_gmt":"2021-01-11T09:00:00","guid":{"rendered":"https:\/\/caam.tech\/?p=294"},"modified":"2022-04-14T17:34:26","modified_gmt":"2022-04-15T00:34:26","slug":"caamtech-synthesizes-3-more-psilocybin-alternatives","status":"publish","type":"post","link":"https:\/\/caam.tech\/caamtech-synthesizes-3-more-psilocybin-alternatives\/","title":{"rendered":"CaaMTech Synthesizes 3 More Psilocybin Alternatives"},"content":{"rendered":"\n

CaaMTech\u2019s latest publication, \u201cPsilacetin derivatives: the methyl-ethyl, methyl-allyl and di\u00adallyl variants of the psilocin prodrug<\/a>,\u201d reveals three novel psilocin prodrug<\/a> variants synthesized by CaaMTech. Psilocin prodrugs may offer practical advantages over psilocybin and could clear some of the roadblocks to mainstream access to psychedelic medicines. The three novel tryptamines are the latest drugs from CaaMTech\u2019s unmatched library of next-generation psychedelics.<\/p>\n\n\n\n

\u201cWhen we surveyed the state of the art in 2017, there were only a few dozen psychedelic tryptamines that had ever<\/em> been made,\u201d explained Dr. Andrew Chadeayne<\/a>, CaaMTech CEO. \u201cOnly a few of them were purified and fully characterized, which limited all downstream research and development.\u201d<\/p>\n\n\n\n

Psilocin is the active metabolite of psilocybin, the psychedelic compound in \u201cmagic mushrooms.\u201d Psilocybin, a prodrug of psilocin, has recently drawn increasing attention for its medicinal properties. Other psilocin prodrugs offer the same benefits as psilocybin, while providing other practical advantages, such as an optimized duration of action. These advantages could provide the key to overcoming hurdles psychedelic medicines face on the road to widespread clinical adoption and public accessibility.<\/p>\n\n\n\n

CaaMTech has emerged as the market leader in psilocin prodrugs. Since first synthesizing crystalline psilacetin in 2019, CaaMTech has made numerous additional psilocin prodrugs through its collaboration with the Manke Lab at UMass Dartmouth<\/a>. These prodrugs are a part of CaaMTech\u2019s rapidly growing library of novel psychedelic drugs and will proceed through CaaMTech\u2019s preclinical drug development pipeline.<\/p>\n\n\n\n

\u201cFrom the beginning, CaaMTech has looked beyond psilocybin and toward the next-generation of psychedelic drugs,\u201d said Dr. Chadeayne, \u201cThanks to Dr. Manke and his team, tomorrow\u2019s psychedelic medicines are in our library today.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"

CaaMTech\u2019s latest paper puts the spotlight on three novel psilocin prodrugs: 4-AcO-MET hydrofumarate, 4-AcO-MALT hydrofumarate & 4-AcO-DALT fumarate<\/p>\n","protected":false},"author":1,"featured_media":296,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[5],"tags":[],"acf":[],"_links":{"self":[{"href":"https:\/\/caam.tech\/wp-json\/wp\/v2\/posts\/294"}],"collection":[{"href":"https:\/\/caam.tech\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/caam.tech\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/caam.tech\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/caam.tech\/wp-json\/wp\/v2\/comments?post=294"}],"version-history":[{"count":1,"href":"https:\/\/caam.tech\/wp-json\/wp\/v2\/posts\/294\/revisions"}],"predecessor-version":[{"id":430,"href":"https:\/\/caam.tech\/wp-json\/wp\/v2\/posts\/294\/revisions\/430"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/caam.tech\/wp-json\/wp\/v2\/media\/296"}],"wp:attachment":[{"href":"https:\/\/caam.tech\/wp-json\/wp\/v2\/media?parent=294"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/caam.tech\/wp-json\/wp\/v2\/categories?post=294"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/caam.tech\/wp-json\/wp\/v2\/tags?post=294"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}